Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

63.32 -1.26 (-1.95%)
Streaming Delayed Price Updated: 10:22 AM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 216,783
Open 64.53
Bid (Size) 63.25 (2)
Ask (Size) 63.42 (4)
Prev. Close 64.58
Today's Range 63.15 - 65.28
52wk Range 38.94 - 86.95
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
3 Top Healthcare Stocks to Buy for June
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool

Performance

YTD
+54.44%
+54.44%
1 Month
+13.15%
+13.15%
3 Month
+32.36%
+32.36%
6 Month
+24.69%
+24.69%
1 Year
-1.40%
-1.40%

More News

Read More
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Via The Motley Fool
3 Disruptors I Love Right Now
Via The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
Via The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for CRISPR Therapeutics's Future
Via Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
Via The Motley Fool
2 Top Trends to Invest $5,000 in Right Now
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
Via The Motley Fool
A Good Week For The Market But A Pause In The Biotech Rally
Via Talk Markets
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
Via The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Via InvestorPlace
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Via MarketBeat
Exposures Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
Via The Motley Fool
2 Soaring Growth Stocks That Could Rocket Even Higher
Via The Motley Fool
Why These 3 Nasdaq Stocks Were Glowing Green This Week
Via The Motley Fool
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades'
Via Benzinga
Why CRISPR Therapeutics Stock Is on Fire Today
Via The Motley Fool
Something Happened In Biotech Last Week
Via Talk Markets
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
Via The Motley Fool
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.